 Matthew Burchill
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 4 | 2021 | 152 | 2.200 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2020 | 246 | 1.240 |
Why?
| | Single-Cell Analysis | 4 | 2021 | 181 | 1.180 |
Why?
| | Liver | 8 | 2021 | 1693 | 1.150 |
Why?
| | Antiviral Agents | 4 | 2021 | 651 | 1.120 |
Why?
| | T-Lymphocytes, Regulatory | 8 | 2021 | 340 | 1.060 |
Why?
| | Lymphatic Vessels | 3 | 2020 | 54 | 1.020 |
Why?
| | Dendritic Cells | 7 | 2021 | 438 | 0.930 |
Why?
| | T-Lymphocyte Subsets | 3 | 2021 | 383 | 0.910 |
Why?
| | Lipoproteins, LDL | 2 | 2020 | 129 | 0.870 |
Why?
| | Hepacivirus | 3 | 2021 | 234 | 0.810 |
Why?
| | Lymphocyte Activation | 2 | 2015 | 1056 | 0.780 |
Why?
| | Interferons | 1 | 2021 | 152 | 0.730 |
Why?
| | Endothelial Cells | 4 | 2021 | 695 | 0.710 |
Why?
| | Isoquinolines | 2 | 2017 | 37 | 0.670 |
Why?
| | Sulfonamides | 3 | 2020 | 447 | 0.670 |
Why?
| | Benzazepines | 2 | 2017 | 37 | 0.670 |
Why?
| | STAT5 Transcription Factor | 8 | 2008 | 42 | 0.650 |
Why?
| | Cell Differentiation | 5 | 2019 | 1709 | 0.640 |
Why?
| | Imidazoles | 2 | 2017 | 215 | 0.610 |
Why?
| | CD27 Ligand | 2 | 2015 | 9 | 0.610 |
Why?
| | Transcriptome | 3 | 2021 | 742 | 0.590 |
Why?
| | Indoles | 2 | 2017 | 309 | 0.560 |
Why?
| | T-Lymphocytes | 2 | 2015 | 1758 | 0.540 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2015 | 27 | 0.540 |
Why?
| | Immunocompromised Host | 1 | 2017 | 197 | 0.530 |
Why?
| | Immunity, Innate | 3 | 2020 | 735 | 0.520 |
Why?
| | Gene Expression Regulation | 3 | 2021 | 2365 | 0.490 |
Why?
| | Receptors, Interleukin-2 | 5 | 2007 | 65 | 0.490 |
Why?
| | Mice | 27 | 2021 | 15085 | 0.470 |
Why?
| | CD4-Positive T-Lymphocytes | 6 | 2015 | 967 | 0.450 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2020 | 688 | 0.440 |
Why?
| | Immunologic Memory | 3 | 2016 | 312 | 0.420 |
Why?
| | Signal Transduction | 14 | 2021 | 4527 | 0.420 |
Why?
| | Mice, Inbred C57BL | 15 | 2021 | 4779 | 0.390 |
Why?
| | Animals | 31 | 2021 | 32158 | 0.390 |
Why?
| | Interleukin-2 | 4 | 2008 | 416 | 0.360 |
Why?
| | Milk Proteins | 3 | 2005 | 36 | 0.350 |
Why?
| | Receptors, Antigen, T-Cell | 4 | 2008 | 631 | 0.340 |
Why?
| | Forkhead Transcription Factors | 2 | 2008 | 170 | 0.330 |
Why?
| | Homeostasis | 4 | 2016 | 577 | 0.310 |
Why?
| | B7-H1 Antigen | 2 | 2020 | 138 | 0.310 |
Why?
| | Self Tolerance | 1 | 2008 | 28 | 0.300 |
Why?
| | Inflammation | 2 | 2018 | 2502 | 0.300 |
Why?
| | Vaccines | 1 | 2012 | 376 | 0.300 |
Why?
| | Trans-Activators | 3 | 2005 | 369 | 0.290 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2007 | 20 | 0.290 |
Why?
| | Borrelia burgdorferi | 2 | 2004 | 12 | 0.280 |
Why?
| | Mice, Knockout | 12 | 2021 | 2608 | 0.280 |
Why?
| | Mice, Transgenic | 9 | 2021 | 1971 | 0.280 |
Why?
| | Lyme Disease | 2 | 2004 | 32 | 0.280 |
Why?
| | Carbamates | 2 | 2017 | 35 | 0.280 |
Why?
| | Pyrrolidines | 2 | 2017 | 56 | 0.270 |
Why?
| | Valine | 2 | 2017 | 74 | 0.270 |
Why?
| | Cytokines | 4 | 2008 | 1858 | 0.270 |
Why?
| | Interferon Type I | 2 | 2018 | 129 | 0.240 |
Why?
| | Interleukin-15 | 4 | 2016 | 76 | 0.240 |
Why?
| | Antigen Presentation | 3 | 2021 | 189 | 0.230 |
Why?
| | Interleukin-17 | 2 | 2004 | 106 | 0.230 |
Why?
| | DNA-Binding Proteins | 3 | 2005 | 1318 | 0.220 |
Why?
| | Bacterial Vaccines | 1 | 2003 | 60 | 0.210 |
Why?
| | Flow Cytometry | 3 | 2019 | 1060 | 0.200 |
Why?
| | Hepatitis, Alcoholic | 1 | 2021 | 13 | 0.200 |
Why?
| | Biomarkers | 3 | 2021 | 3474 | 0.200 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2007 | 796 | 0.200 |
Why?
| | Lymph Nodes | 2 | 2021 | 423 | 0.200 |
Why?
| | Antigens | 2 | 2021 | 322 | 0.190 |
Why?
| | Autoimmunity | 1 | 2007 | 823 | 0.190 |
Why?
| | Janus Kinase 1 | 1 | 2020 | 22 | 0.190 |
Why?
| | Janus Kinase 2 | 1 | 2020 | 30 | 0.190 |
Why?
| | Intercellular Junctions | 1 | 2020 | 34 | 0.180 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2021 | 54 | 0.180 |
Why?
| | Azetidines | 1 | 2020 | 31 | 0.180 |
Why?
| | Dermis | 1 | 2020 | 30 | 0.180 |
Why?
| | Proteostasis | 1 | 2020 | 20 | 0.180 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 390 | 0.180 |
Why?
| | Cell Movement | 3 | 2020 | 867 | 0.180 |
Why?
| | Radiation Tolerance | 1 | 2021 | 92 | 0.180 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 145 | 0.180 |
Why?
| | Permeability | 1 | 2020 | 151 | 0.180 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 174 | 0.170 |
Why?
| | Immunity | 1 | 2020 | 125 | 0.170 |
Why?
| | Disease Models, Animal | 2 | 2020 | 3587 | 0.170 |
Why?
| | Tumor Suppressor Proteins | 2 | 2020 | 286 | 0.170 |
Why?
| | Cholesterol, Dietary | 1 | 2019 | 15 | 0.170 |
Why?
| | Interleukin-1beta | 1 | 2021 | 370 | 0.170 |
Why?
| | Diet, High-Fat | 1 | 2020 | 225 | 0.170 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 153 | 0.160 |
Why?
| | Kupffer Cells | 1 | 2019 | 45 | 0.160 |
Why?
| | Endothelium, Lymphatic | 1 | 2018 | 12 | 0.160 |
Why?
| | Humans | 14 | 2021 | 115859 | 0.150 |
Why?
| | Cell Proliferation | 5 | 2018 | 2196 | 0.150 |
Why?
| | Killer Cells, Natural | 2 | 2015 | 381 | 0.150 |
Why?
| | Interleukin-6 | 1 | 2021 | 677 | 0.150 |
Why?
| | Immunotherapy | 1 | 2021 | 481 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2020 | 272 | 0.140 |
Why?
| | Homeodomain Proteins | 1 | 2020 | 465 | 0.140 |
Why?
| | Male | 8 | 2021 | 56103 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 638 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 425 | 0.140 |
Why?
| | Hepatocytes | 1 | 2017 | 197 | 0.140 |
Why?
| | Bystander Effect | 1 | 2016 | 15 | 0.140 |
Why?
| | Proteomics | 1 | 2021 | 855 | 0.130 |
Why?
| | Down Syndrome | 1 | 2020 | 336 | 0.130 |
Why?
| | CD3 Complex | 1 | 2015 | 92 | 0.130 |
Why?
| | Receptors, Interleukin-7 | 2 | 2006 | 26 | 0.130 |
Why?
| | Membrane Glycoproteins | 2 | 2021 | 433 | 0.120 |
Why?
| | Coculture Techniques | 1 | 2015 | 204 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 1 | 2020 | 789 | 0.120 |
Why?
| | Melanoma | 1 | 2021 | 649 | 0.120 |
Why?
| | Hepatitis C | 1 | 2017 | 229 | 0.120 |
Why?
| | Receptors, Immunologic | 1 | 2015 | 203 | 0.120 |
Why?
| | B-Lymphocyte Subsets | 2 | 2005 | 67 | 0.120 |
Why?
| | Viral Load | 1 | 2015 | 406 | 0.110 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 352 | 0.110 |
Why?
| | Antigens, Viral | 1 | 2014 | 177 | 0.110 |
Why?
| | Viral Vaccines | 1 | 2014 | 89 | 0.110 |
Why?
| | Chronic Disease | 1 | 2019 | 1598 | 0.110 |
Why?
| | Alum Compounds | 1 | 2013 | 22 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 962 | 0.110 |
Why?
| | Vaccines, Subunit | 1 | 2012 | 41 | 0.100 |
Why?
| | Virus Diseases | 1 | 2014 | 200 | 0.100 |
Why?
| | Immunity, Humoral | 1 | 2012 | 112 | 0.100 |
Why?
| | Cross-Priming | 1 | 2011 | 19 | 0.100 |
Why?
| | Aged | 3 | 2019 | 19292 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2013 | 206 | 0.100 |
Why?
| | Toll-Like Receptor 7 | 1 | 2011 | 35 | 0.100 |
Why?
| | DNA | 2 | 2021 | 1357 | 0.100 |
Why?
| | Immunity, Cellular | 1 | 2012 | 263 | 0.090 |
Why?
| | OX40 Ligand | 1 | 2010 | 10 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2004 | 733 | 0.090 |
Why?
| | Tumor Burden | 2 | 2021 | 261 | 0.090 |
Why?
| | Base Sequence | 2 | 2020 | 2121 | 0.090 |
Why?
| | Prospective Studies | 1 | 2021 | 6276 | 0.090 |
Why?
| | Middle Aged | 3 | 2019 | 27078 | 0.090 |
Why?
| | Poly I-C | 2 | 2020 | 52 | 0.090 |
Why?
| | Cell Lineage | 2 | 2008 | 310 | 0.080 |
Why?
| | Lymphopoiesis | 1 | 2008 | 24 | 0.080 |
Why?
| | Sequence Analysis | 1 | 2008 | 35 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2019 | 6434 | 0.080 |
Why?
| | CD28 Antigens | 1 | 2008 | 46 | 0.080 |
Why?
| | Pyrazoles | 2 | 2021 | 362 | 0.080 |
Why?
| | Cell Division | 3 | 2004 | 760 | 0.080 |
Why?
| | Interleukins | 1 | 2008 | 237 | 0.070 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 271 | 0.070 |
Why?
| | Female | 5 | 2020 | 60070 | 0.070 |
Why?
| | Cell Survival | 4 | 2018 | 1024 | 0.070 |
Why?
| | Toll-Like Receptors | 2 | 2020 | 166 | 0.060 |
Why?
| | Animals, Newborn | 1 | 2008 | 780 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2021 | 3914 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2007 | 1130 | 0.060 |
Why?
| | Gene Deletion | 1 | 2007 | 356 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1153 | 0.060 |
Why?
| | Lyme Disease Vaccines | 1 | 2004 | 3 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2021 | 2749 | 0.060 |
Why?
| | Thymus Gland | 1 | 2005 | 298 | 0.060 |
Why?
| | Up-Regulation | 2 | 2005 | 824 | 0.060 |
Why?
| | Arthritis, Infectious | 1 | 2004 | 50 | 0.060 |
Why?
| | Neoplasms | 1 | 2017 | 2114 | 0.060 |
Why?
| | Phosphorylation | 3 | 2020 | 1562 | 0.060 |
Why?
| | Crosses, Genetic | 1 | 2003 | 141 | 0.060 |
Why?
| | Receptors, Interleukin-17 | 1 | 2003 | 5 | 0.060 |
Why?
| | Mutation | 2 | 2020 | 3371 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2003 | 97 | 0.060 |
Why?
| | Receptors, Interleukin | 1 | 2003 | 39 | 0.060 |
Why?
| | Alleles | 1 | 2006 | 817 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1169 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2796 | 0.050 |
Why?
| | Eye Proteins | 1 | 2021 | 74 | 0.050 |
Why?
| | Phosphorothioate Oligonucleotides | 1 | 2021 | 9 | 0.050 |
Why?
| | Caveolae | 1 | 2021 | 16 | 0.050 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 17 | 0.050 |
Why?
| | Models, Immunological | 1 | 2021 | 91 | 0.050 |
Why?
| | Antibodies | 1 | 2003 | 374 | 0.050 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2021 | 66 | 0.050 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 39 | 0.050 |
Why?
| | Chemokine CCL21 | 1 | 2020 | 13 | 0.050 |
Why?
| | Ovalbumin | 1 | 2021 | 166 | 0.050 |
Why?
| | Receptors, CCR7 | 1 | 2020 | 24 | 0.050 |
Why?
| | Nitriles | 1 | 2021 | 152 | 0.050 |
Why?
| | Lymphocyte Depletion | 1 | 2021 | 115 | 0.050 |
Why?
| | Adult | 2 | 2019 | 30814 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2021 | 324 | 0.040 |
Why?
| | Endocytosis | 1 | 2021 | 152 | 0.040 |
Why?
| | Melanoma, Experimental | 1 | 2021 | 118 | 0.040 |
Why?
| | Spleen | 2 | 2016 | 492 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2020 | 142 | 0.040 |
Why?
| | Chemotaxis | 1 | 2020 | 132 | 0.040 |
Why?
| | Polymerization | 1 | 2020 | 119 | 0.040 |
Why?
| | Cell Count | 1 | 2020 | 304 | 0.040 |
Why?
| | Glycoproteins | 1 | 2021 | 311 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1244 | 0.040 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 157 | 0.040 |
Why?
| | Exons | 1 | 2020 | 303 | 0.040 |
Why?
| | Purines | 1 | 2020 | 159 | 0.040 |
Why?
| | Protein Domains | 1 | 2020 | 208 | 0.040 |
Why?
| | Interferon-alpha | 1 | 2020 | 187 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 414 | 0.040 |
Why?
| | Immune Tolerance | 1 | 2021 | 331 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2004 | 771 | 0.040 |
Why?
| | Hepatitis | 1 | 2019 | 45 | 0.040 |
Why?
| | Vaccination | 2 | 2004 | 1209 | 0.040 |
Why?
| | Pyrimidines | 1 | 2021 | 376 | 0.040 |
Why?
| | Actins | 1 | 2020 | 384 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 424 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1264 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1127 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2021 | 369 | 0.040 |
Why?
| | Amino Acids | 1 | 2020 | 456 | 0.040 |
Why?
| | Peptide Fragments | 1 | 2021 | 675 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2019 | 449 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 148 | 0.030 |
Why?
| | Growth Inhibitors | 2 | 2005 | 45 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2014 | 82 | 0.030 |
Why?
| | Macrophages | 1 | 2021 | 1282 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2021 | 2581 | 0.030 |
Why?
| | Autoantigens | 1 | 2016 | 399 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 2859 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2423 | 0.030 |
Why?
| | Receptors, Interleukin-12 | 1 | 2011 | 6 | 0.020 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2011 | 22 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 280 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 639 | 0.020 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2011 | 90 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1442 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6182 | 0.020 |
Why?
| | Vaccinia virus | 1 | 2010 | 30 | 0.020 |
Why?
| | CD40 Antigens | 1 | 2010 | 80 | 0.020 |
Why?
| | Listeria monocytogenes | 1 | 2010 | 110 | 0.020 |
Why?
| | Interleukin-7 | 1 | 2008 | 44 | 0.020 |
Why?
| | Immunization | 1 | 2010 | 402 | 0.020 |
Why?
| | Receptors, Interleukin-15 | 1 | 2006 | 3 | 0.020 |
Why?
| | Transcription Factors | 2 | 2005 | 1535 | 0.020 |
Why?
| | Resting Phase, Cell Cycle | 1 | 2006 | 15 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2006 | 200 | 0.020 |
Why?
| | PAX5 Transcription Factor | 1 | 2005 | 12 | 0.020 |
Why?
| | bcl-X Protein | 1 | 2005 | 39 | 0.020 |
Why?
| | Bone Marrow | 1 | 2006 | 248 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2004 | 43 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 213 | 0.010 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2004 | 147 | 0.010 |
Why?
| | PTEN Phosphohydrolase | 1 | 2004 | 142 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2004 | 332 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2004 | 399 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 754 | 0.010 |
Why?
| | Down-Regulation | 1 | 2004 | 605 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2004 | 356 | 0.010 |
Why?
| | Stem Cells | 1 | 2005 | 546 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 609 | 0.010 |
Why?
| | Protein Binding | 1 | 2005 | 1918 | 0.010 |
Why?
|
|
Burchill's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|